Attovia Therapeutics, Inc. (NASDAQ:ATTO – Get Free Report) major shareholder Redmile Group, Llc acquired 400,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were bought at an average cost of $17.00 per share, for a total transaction of $6,800,000.00. Following the transaction, the insider owned 1,182,854 shares of the company’s stock, valued at $20,108,518. This represents a 51.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Attovia Therapeutics Stock Performance
ATTO stock traded down $0.21 on Friday, hitting $20.17. 237,906 shares of the company’s stock were exchanged, compared to its average volume of 325,553. Attovia Therapeutics, Inc. has a 12-month low of $18.64 and a 12-month high of $22.79.
Hedge Funds Weigh In On Attovia Therapeutics
A hedge fund recently raised its position in Attovia Therapeutics stock. BlackRock Inc. raised its position in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO – Free Report) by 23.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 164,358 shares of the company’s stock after purchasing an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent reporting period.
About Attovia Therapeutics
Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.
Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.
Further Reading
- Five stocks we like better than Attovia Therapeutics
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Attovia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Attovia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
